How to identify whether a patient is resistant to osimertinib

Osimertinib, as a targeted therapy for non-small cell lung cancer, is particularly effective in patients carrying EGFR T790M mutation. However, as the treatment progresses, patients may develop resistance to osimertinib.

To identify whether a patient has developed resistance to osimertinib, the first step is to carefully observe the patient's clinical manifestations. If a patient's original symptoms, such as cough or dyspnea, do not improve as expected after taking osimertinib, or even show a worsening trend, this may indicate the development of drug resistance. Especially when patients continue to experience symptoms such as severe cough, chest pain, or respiratory distress, we should be highly vigilant that the drug may have expired.

In addition to symptom observation, we can also objectively evaluate the therapeutic effect of drugs through regular imaging examinations. Using high-end imaging technologies such as CT or PET-CT, we can clearly observe changes in the size and number of tumors. If it is found that the tumor does not shrink, or even shows signs of growth or spread, this usually means that the therapeutic effect of osimertinib is weakening and the patient may have developed resistance to the drug.

In addition, monitoring changes in tumor markers is also an important means of judging drug resistance. If a patient's tumor marker levels do not decrease as expected after treatment with osimertinib, but instead show an upward trend, this may also indicate that the drug has lost its efficacy and the patient has developed drug resistance.

Importantly, the emergence of drug resistance does not equate to the end of treatment. Once drug resistance is detected, the medical team will flexibly adjust the treatment strategy according to the patient's specific condition, such as replacing other targeted drugs or combining multiple treatments to continue to curb the spread of the disease.

In summary, to accurately determine whether a patient has developed resistance to osimertinib, we need to comprehensively consider changes in symptoms, imaging feedback, and the dynamics of tumor markers. At the same time, close cooperation and active communication between patients and the medical team are also key to ensuring maximum treatment effects.